Summary: Eli Lilly announced that its weight-loss drug Zepbound (tirzepatide) reduced the severity of obstructive sleep apnea (OSA) by up to 63% in adults with obesity in two phase 3 trials. The drug improved sleep apnea symptoms in patients using and not using PAP therapy. Based … [Read more...]